Acute S-ketamine application does not alter cerebral [18F]altanserin binding: a pilot PET study in humans (Q40207601)

18 September 2017

Acute S-ketamine application does not alter cerebral [18F]altanserin binding: a pilot PET study in humans (English)

1 reference

18 September 2017

D Elmenhorst

5

0 references

Andreas Bauer

object named as

A Bauer

9

0 references

Rene Hurlemann

object named as

R Hurlemann

2

0 references

Karl Zilles

7

object named as

K Zilles

1 reference

18 September 2017

8

K Zilles

1 reference

18 September 2017

A Matusch

1

1 reference

18 September 2017

E Rota Kops

3

1 reference

18 September 2017

O H Winz

4

1 reference

18 September 2017

H Herzog

6

1 reference

18 September 2017

1 June 2007

1 reference

Journal of Neural Transmission

18 September 2017

1 reference

18 September 2017

114

1 reference

18 September 2017

1433-1442

1 reference

18 September 2017

11

1 reference

https://scigraph.springernature.com/pub.10.1007/s00702-007-0751-3

18 September 2017

0 references

cites work

The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors

1 reference

https://api.crossref.org/works/10.1007%2FS00702-007-0751-3

Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-007-0751-3

Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-007-0751-3

Serotonin 5HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: results in young normal controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-007-0751-3

Schizophrenia, ketamine and cannabis: evidence of overlapping memory deficits

21 January 2018

1 reference

12 December 2020

[18F]altanserin binding to human 5HT2A receptors is unaltered after citalopram and pindolol challenge

1 reference

12 December 2020

NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia

1 reference

12 December 2020

Selective cognitive impairments associated with NMDA receptor blockade in humans

1 reference

12 December 2020

Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes

1 reference

12 December 2020

Molecular biology of 5-HT receptors

1 reference

12 December 2020

NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.

1 reference

12 December 2020

Fenfluramine evokes 5-HT2A receptor-mediated responses but does not displace [11C]MDL 100907: small animal PET and gene expression studies

1 reference

12 December 2020

Influence of synaptic serotonin level on [18F]altanserin binding to 5HT2 receptors in man.

1 reference

12 December 2020

Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis.

1 reference

12 December 2020

Multiple conformations of native and recombinant human 5-hydroxytryptamine(2a) receptors are labeled by agonists and discriminated by antagonists.

1 reference

12 December 2020

Stereoselective effects of ketamine on dopamine, serotonin and noradrenaline release and uptake in rat brain slices.

1 reference

12 December 2020

A complete remote-control system for reliable preparation of [18F]altanserin.

1 reference

12 December 2020

Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects.

1 reference

12 December 2020

Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction

1 reference

12 December 2020

Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach.

1 reference

12 December 2020

PET quantification of 5-HT2A receptors in the human brain: a constant infusion paradigm with [18F]altanserin

1 reference

12 December 2020

Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography

1 reference

12 December 2020

The diagnosis and assessment of individuals prodromal for schizophrenic psychosis.

1 reference

12 December 2020

Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans

1 reference

12 December 2020

Quantification of 5-HT2A receptors in the human brain using [18F]altanserin-PET and the bolus/infusion approach

1 reference

12 December 2020

[3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role.

1 reference

12 December 2020

Antidepressant effects of ketamine in depressed patients

1 reference

12 December 2020

Serotonin model of schizophrenia: emerging role of glutamate mechanisms

1 reference

12 December 2020

NMDA-receptor activity visualized with (S)-[N-methyl-11C]ketamine and positron emission tomography in patients with medial temporal lobe epilepsy.

1 reference

12 December 2020

Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review

1 reference

12 December 2020

Effects of ketamine in normal and schizophrenic volunteers

1 reference

12 December 2020

Serotonin 5-HT2 receptor imaging in major depression: focal changes in orbito-insular cortex

1 reference

12 December 2020

Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function

1 reference

12 December 2020

Depression: comfortably numb.

1 reference

12 December 2020

Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers.

1 reference

12 December 2020

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

1 reference

12 December 2020

Automatic Synthesis of [18F]Altanserin, a Radiopharmaceutical for Positron Emission Tomographic Studies of the Serotonergic Type-2 Receptors

1 reference

12 December 2020

Molecular cloning and expression of a dopamine D2 receptor from human retina

1 reference

12 December 2020

Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: A PET study using [(18)F]setoperone

1 reference

12 December 2020

Binding characteristics of the 5-HT2A receptor antagonists altanserin and MDL 100907.

1 reference

12 December 2020

No-carrier-added nucleophilic 18F-labelling in an electrochemical cell exemplified by the routine production of [18F]altanserin.

1 reference

12 December 2020

AT-1015, a newly synthesized 5-HT2 receptor antagonist, dissociates slowly from the 5-HT2 receptor sites in rabbit cerebral cortex membrane

1 reference

12 December 2020

Interference of anaesthetics with radioligand binding in neuroreceptor studies

1 reference

12 December 2020

Ethical parameters of challenge studies inducing psychosis with ketamine.

1 reference

12 December 2020

The dynamin-dependent, arrestin-independent internalization of 5-hydroxytryptamine 2A (5-HT2A) serotonin receptors reveals differential sorting of arrestins and 5-HT2A receptors during endocytosis

1 reference

12 December 2020

Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging

1 reference

12 December 2020

10.1007/S00702-007-0751-3

Identifiers

DOI

1 reference

Dimensions Publication ID

18 September 2017

0 references

1 reference